Search research articles
Contact Us
Filters
Showing results (61-70 of 140) with videos related to
Page
of 14
Sort By:
The Journal of Clinical Investigation
|
June 19, 2025
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
Soumya Poddar, Jiali Yan, Gayatri Tiwari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2023
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
Michael D Jain, David B Miklos, Caron A Jacobson, et al.
Blood Advances
|
February 5, 2024
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Armin Ghobadi, Javier Munoz, Jason R Westin, et al.
The Lancet. Rheumatology
|
January 31, 2025
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study
Kathleen M M Vanni, Kaitlin R McCarter, Xiaosong Wang, et al.
Leukemia & Lymphoma
|
June 1, 2016
Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant
Emily F Mason, Ronald D Brown, David P Szeto, et al.
Blood
|
November 17, 2021
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome
Matthew S Davids, Kerry A Rogers, Svitlana Tyekucheva, et al.
British Journal of Haematology
|
May 2, 2023
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD
Marshall McKenna, Narendranath Epperla, Armin Ghobadi, et al.
Blood Advances
|
October 9, 2020
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Frederick L Locke, John M Rossi, Sattva S Neelapu, et al.
Brain : a Journal of Neurology
|
March 21, 2019
Neurological toxicities associated with chimeric antigen receptor T-cell therapy
Daniel B Rubin, Husain H Danish, Ali Basil Ali, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 28, 2014
Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease
Caron A Jacobson, Lixian Sun, Haesook T Kim, et al.
Page
of 14
Search research articles
Search
Showing results (61-70 of 140) with videos related to
Sort By:
Page
of 14
The Journal of Clinical Investigation
|
June 19, 2025
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
Soumya Poddar, Jiali Yan, Gayatri Tiwari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2023
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
Michael D Jain, David B Miklos, Caron A Jacobson, et al.
Blood Advances
|
February 5, 2024
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Armin Ghobadi, Javier Munoz, Jason R Westin, et al.
The Lancet. Rheumatology
|
January 31, 2025
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study
Kathleen M M Vanni, Kaitlin R McCarter, Xiaosong Wang, et al.
Leukemia & Lymphoma
|
June 1, 2016
Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant
Emily F Mason, Ronald D Brown, David P Szeto, et al.
Blood
|
November 17, 2021
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome
Matthew S Davids, Kerry A Rogers, Svitlana Tyekucheva, et al.
British Journal of Haematology
|
May 2, 2023
Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD
Marshall McKenna, Narendranath Epperla, Armin Ghobadi, et al.
Blood Advances
|
October 9, 2020
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Frederick L Locke, John M Rossi, Sattva S Neelapu, et al.
Brain : a Journal of Neurology
|
March 21, 2019
Neurological toxicities associated with chimeric antigen receptor T-cell therapy
Daniel B Rubin, Husain H Danish, Ali Basil Ali, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
January 28, 2014
Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease
Caron A Jacobson, Lixian Sun, Haesook T Kim, et al.
Page
of 14